Journal article
The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.
Abstract
In an attempt to circumvent innate or acquired tumor-cell resistance to chemotherapy, patients with small-cell lung cancer (SCLC) were treated with induction therapy that incorporated two active and potentially non-cross-resistant chemotherapy regimens on two National Cancer Institute of Canada (NCI-C) trials. Patients with limited disease (LD) SCLC were treated with cyclophosphamide, doxorubicin (Adriamycin [Adria Laboratories, Columbus, …
Authors
Evans WK; Feld R; Murray N; Pater J; Shelley W; Willan A; Osoba D; Levitt M; Coy P; Hodson I
Journal
Seminars in Oncology, Vol. 13, No. 3 Suppl 3, pp. 10–16
Publication Date
9 1986
ISSN
0093-7754